The TruSight RNA Pan-Cancer panel provides a comprehensive analysis of the cancer transcriptome. Targeting 1385 cancer-related transcripts and genes known to be involved in gene fusions, TruSight RNA Pan-Cancer enables analysis of cancer samples including FFPE tissues and other limited samples. It offers:
RNA-Seq using next-generation sequencing (NGS) offers the ability to capture all relevant transcripts in a single assay. Unlike traditional array-based approaches, which have limited sensitivity, targeted RNA-Seq with the TruSight RNA Pan-Cancer is a sensitive approach that detects low levels of expression and identifies novel variants. In addition, TruSight RNA Pan-Cancer detects gene fusions with both known and novel gene fusion partners.
The panel is compatible with FFPE tissue and accommodates as little as 10 ng of total RNA input (20ng from FFPE). The focus on a subset of relevant genes enables RNA-Seq with high sensitivity at 8 samples per run on a desktop sequencer, allowing cost-effective access to NGS for any lab. Download gene list »
By enabling targeted RNA-Seq on desktop sequencers, TruSight RNA Pan-Cancer provides an economical solution for cancer researchers needing to detect the functionally relevant changes occurring in cancer. Analysis can be performed using the new BaseSpace App, RNA-Seq Alignment. The intuitive RNA-Seq Alignment App performs fusion calling, variant detection and provides gene expression profiles offering sample-to-data solutions to all cancer researchers.
For more information on the RNA-Seq Alignment App click here »
10 ng of human reference RNA (UHR), human reference brain RNA (Brain), cell line RNA (MCF7), and 20 ng of breast tumor FFPE RNA (BT) were prepared using the TruSight RNA Pan-Cancer Panel and sequenced on the MiSeq System. Read mapping and fusion calling were performed using the RNA-Seq Alignment App with STAR aligner on BaseSpace Sequence Hub.
Human reference RNA (HBRR and UHRR), cell line RNA (MCF7), and breast tumor RNA samples were prepared using the TruSight RNA Pan-Cancer panel, and 8 samples were sequenced on the MiniSeq System at a 2x76bp read length with single indexing. The total yield was 4.2 Gb with 96.8% of bases at or above Q30.
|Description||Document Type||File Info|
|Evaluating RNA Quality from FFPE Samples||Technical Note||PDF(1 MB)|
|TruSight RNA Pan-Cancer Panel||Data Sheet||PDF(< 1 MB)|
Catalog IDs: RS-303-1002, RS-303-1003, MS-102-3001, 20005611